| Accession |
PRJCA017910 |
| Title |
Open clinical data of irinotecan hydrochloride liposome combined with 5-FU/LV second-line treatment project for locally advanced or metastatic pancreatic cancer after failure of Gemcitabine treatment |
| Relevance |
Medical |
| Data types |
Random survey
|
| Organisms |
Homo sapiens
|
| Description |
Liposomal irinotecan has shown promising antitumour activity in patients with advanced or metastatic pancreatic ductal adenocarcinoma who have been treated with gemcitabine-based therapies. This phase 3 trial assessed the efficacy and safety of a novel liposomal irinotecan HR070803 in combination with 5-fluorouracil and leucovorin in this population. |
| Sample scope |
Multispecies |
| Release date |
2023-12-31 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Jiangsu Hengrui Pharmaceutical Co., Ltd
|
|
HR-IRI-APC
|
|
|
|
| Submitter |
binbin
liu (binbin.liu@hengrui.com)
|
| Organization |
jiang su hengrui medicine co,LTD |
| Submission date |
2023-05-26 |
